

Jack Farr, Brian J. Cole, Michael J. Salata, Marco Collarile, and Sarvottam Bajaj

42.1 Introduction

The appropriate treatment of patients with anterior knee pain starts with a thorough clinical history and a carefully conducted physical examination. A thorough assessment of the chondral defects and concomitant patho-mechanical factors is critical to the success of any restorative procedure. Co-morbidities such as patella alta, trochlear dysplasia, increased lateral position of the tibial tubercle relative to the femoral sulcus, and secondary soft tissue problems, such as a hypoplastic vastus medialis muscle or a contracted lateral retinaculum must be clearly defined. The standard treatment algorithms used for tibial or femoral chondral lesions cannot be directly extrapolated to the patellofemoral articulation. As an example, Brittberg and Peterson et al. reported successful outcomes for the tibiofemoral joint with autologous cultured chondrocyte transplantation (ACT); however, the same technique reported suboptimal outcomes in the patellofemoral joint as concomitant pathology such as malalignment was not addressed.¹ Peterson et al. next added treatment of the comorbidities to PF ACT and reported markedly improved outcomes.⁷

Chondral defects in the patellofemoral joint have varied etiologies. For example, the chondrosis may be genetically related, as with focal or diffuse degeneration secondary to trauma (direct impact or a result of

patellofemoral instability) or secondary to repetitive microtrauma (e.g., excessive loads such as in jumping sports), or related to the cumulative microtrauma of biomechanical abnormalities (e.g., chronic patellar subluxation). High-grade (grades III and IV) focal chondral defects (Table 42.1) are reported to occur between 11% and 20% in patients undergoing knee arthroscopy. Of these defects, 11–23% involved the patella and 6–15% were trochlear.^{1,10,20} Not all of these lesions were symptomatic. In fact, some patients are asymptomatic even at very high functional levels. Kaplan et al. performed MRIs on asymptomatic NBA basketball players and found articular cartilage lesions in 47% of these players, with 50% of these lesions classified as high grade (III or IV). The patella was affected in 35%, and the trochlea in 25% of these players who were asymptomatic.²³ Similarly, Walczak et al. found abnormal cartilage signal on MRI in 57% of asymptomatic NBA players with a 7% incidence of focal defects.⁴²

Just as with other PF problems, symptoms and pathology have incomplete correlations. It is not entirely clear why some patients with PF chondral lesions present with pain while others can perform at a high level. Ficat and Hungeford proposed that the elevated intraosseous pressures seen in the face of an articular cartilage lesion could be the source of pain and today with MRI, it is not uncommon to see areas of bone overload associated with chondral lesions as evidenced by “bone bruises.”³¹ As noted, the articular cartilage is aneural, so pain other than bone may emanate from the soft tissues, including the joint capsule, ligaments, tendons, and synovium. In addition to mechanical factors, pain may be initiated in part by irritation from chondral debris, which activates an inflammatory and nociceptive response. As the true pain generator is often not well defined,

[AU1] B.J. Cole (✉)
Departments of Orthopaedics & Anatomy and Cell Biology,
Division of Sports Medicine, Cartilage Restoration Center at
Rush, Rush University Medical Center, Chicago, IL, USA
e-mail: bcole@rushortho.com

t1.1 **Table 42.1** Summary of modified outerbridge and ICRS chondral grading scales

t1.2	Grade	Modified outerbridge	ICRS	
t1.3	Grade 0	Normal	Normal	
	Grade 1	Softening	A: Near normal B: Soft intact or superficial open lesion	t1.4 t1.5
t1.6	Grade 2	Open fissures, fibrillation to 50% depth	Abnormal lesion to <50% cartilage depth	
	Grade 3	Open fissure fibrillation to palpable bone (>50% depth)	Severely abnormal A: >50% cartilage depth B: Down to calcified layer C: To but not through bone	t1.7 t1.8 t1.9 t1.10
	Grade 4	Exposed bone	Severely abnormal full-thickness cartilage loss and bone loss	t1.11 t1.12
t1.13	Notes		Add size and site of lesion	

70 it is crucial to thoroughly evaluate all potential
71 sources of discomfort before attributing symptoms
72 to a chondral defect. This chapter presents the sys-
73 tematic approach to decision-making process for,
74 and surgical treatment of, chondral defects of the PF
75 compartment.

76 42.2 History

77 A careful clinical history is the first step necessary to
78 make an accurate diagnosis. Patients may report a his-
79 tory of either an insidious onset of symptoms or acute
80 onset after trauma. In addition, it is not uncommon for
81 the mechanism of the PF chondral pathology to be
82 unknown. In general, patients with patellofemoral
83 pathology can be divided in two main groups: anterior
84 knee pain and patellar instability. It is critical to deter-
85 mine which of the patient's symptoms are most promi-
86 nent: pain or instability, noting that these are not
87 mutually exclusive. The approach to these two subsets
88 is somewhat different and thus the need to fully explore
89 the patient's main complaint is presented. The charac-
90 ter of the anterior knee pain is important to elicit from
91 the patient. Pain from the anterior soft tissues is often
92 described as acute, episodic, and/or localized/poorly
93 localized. Document what activities and positions
94 aggravated the pain. The patient can often perform
95 maneuvers in the office to reproduce pain. Pain due to
96 a chondral etiology mediates through the same tissues
97 that cause pain for other PF pathologies. It is often
98 poorly localized and may be exacerbated by prolonged

sitting ("movie theatre sign"). Severe, unremitting pain 99
that is out of proportion to the patient's exam could be 100
suggestive of a more possible complex regional pain 101
syndrome. 102

Any history of knee trauma is important. Direct 103
impact injury such as a slip, fall, or "dashboard" 104
type injury may result in anterior knee pain and may 105
damage the patellar or trochlear cartilage even with- 106
out bone injury. Patellar dislocations may cause 107
damage to the distal medial patellar cartilage and/or 108
lateral femoral condyle. An indirect mechanism is 109
seen with posterior cruciate ligament (PCL) injury. 110
With the posterior displacement of the tibia, PF 111
compartment joint reactive forces are increased.¹³ 112
Over time this patellofemoral overload may lead 113
to chondral changes and symptoms of anterior 114
knee pain. 115

When evaluating the patient with a chief complaint 116
of instability, it is important to determine the amount 117
of energy associated with the first dislocation episode. 118
If the initial episode was a very low energy episode, it 119
should trigger the physician to carefully evaluate for 120
predisposing factors such as generalized ligamentous 121
laxity, patellar alta, trochlear dysplasia, or malalign- 122
ment. For higher energy dislocations, there is increased 123
risk of chondral pathology with a lower likelihood of 124
significant predisposing anatomic factors. The fre- 125
quency of and most recent dislocation episode should 126
be recorded, as well as the degree of pain and effusion 127
between instability episodes. Interval pain and effu- 128
sion symptoms may suggest chondral damage from the 129
recurrent dislocations. In the patient with frequent dis- 130
locations, not only is there patholaxity of the soft 131

tissue restraints, there may be significant PF dysplasia and patella alta that will necessitate a more comprehensive reconstructive procedure. It is important to determine whether the patient is having true dislocation episodes or if they are experiencing subluxations or another phenomenon such as “giving way”.¹³ This may, indeed, represent patellar instability, but can also be related to a pain reflex causing quadriceps inhibition, secondary to ligament deficiency (e.g., ACL deficiency) or intra-articular effusion that inhibits full quadriceps activation.³⁷ Patients often report crepitus. This has poor correlation with chondral pathology and may be a result of many factors such as: chondrosis, synovial impingement, or scar tissue. Some patients will also complain of mechanical symptoms of locking or catching. In contrast to the symptoms caused by meniscal pathology, mechanical symptoms from the patellofemoral joint usually occur during activity which loads the patellofemoral compartment such as walking down stairs.

Any previous surgical interventions should be documented. It is ideal if the operative reports and the intraoperative arthroscopy images are obtained and reviewed. The date of the procedure is also very important. If it has been a prolonged period since arthroscopic evaluation, a repeat arthroscopy may be warranted to confirm the diagnosis and to define the lesions by location, region, and grade.

42.3 Physical Examination

A focused and detailed physical examination is just as important as the clinical history. The examination entails evaluation of the entire kinetic chain from the foot (pronation vs. cavus) to the tibia (external torsion) to the knee and PF specific exams of the hip. Increased internal rotation increases the suspicion of excessive hip anteversion to the core proximal musculature which will also include the low back and pelvis. Evaluation of muscle weakness of the hip abductors, hip extensors, and pelvic stabilizers is essential. Weakness of these muscles is evaluated by asking the patient to do a single-leg stance on the affected limb which results in a pelvic drop on the contralateral side. Inspection for any deformity or surgical scars should be the first step in the exam. An evaluation of gait should also be performed to assess for any incongruity or abnormality.

Both legs should be examined to evaluate for symmetry. The location of the patient’s pain should be identified if possible and contributing structures should be carefully assessed. An evaluation for patellar instability should be performed on all patients presenting with symptoms localized to the anterior knee.

Special tests for the PF compartment have been described. Retinacular tightness can be evaluated with the patellar glide and tilt tests. With the knee flexed to 30° the patella is displaced medially. If there is limited medial movement associated with lateral PF facet pain, this is pathognomic of excessive lateral tightness.¹³ Lateral retinacular tightness is common in patients with anterior knee pain and is the hallmark of the excessive lateral pressure syndrome described by Ficat.¹² Fulkerson reported tenderness over the lateral retinaculum in 90% of the patients in his series of anterior knee pain.¹⁴ The patellar grind test is an axial compression of the patella on the trochlea and is positive if pain is reproduced and is often positive in the setting of a chondral defect. This test is performed in various angles of flexion in order to establish the location of the chondral defect if present. As the contact area moves from proximal to distal with knee motion, pain near extension is indicative of a chondral defect in the distal part of patella or trochlea; if the pain is elicited at 90° of flexion, the chondral defect is localized to the proximal aspect of patella or trochlea. The sustained knee flexion test is performed by having the patient flex the knee against resistance for 45 s and then having them extend the knee after a period of 15–30 s.¹⁹ The test is considered positive if pain is reported during the extension period. Patellar and quadriceps tendinosis can present as anterior knee pain, so it is important to palpate the proximal and distal poles of the patella. Hoffa’s fat pad should be considered as a source of pain especially in the patient who has undergone a previous arthroscopy.¹⁷

A patient presenting with instability will usually experience a lateral subluxation or dislocation. The patellar glide test is used to assess the medial and lateral displacement of the patella. It is positive if the patella can be significantly displaced in three or more quadrants.¹³ Fairbank’s patellar apprehension test, when positive, suggests that instability is a significant problem for the patient. The test is positive when the patient has a defensive contracture of quadriceps during lateral patellar displacement at 20°–30° of flexion. Medial instability is often a consequence of an unnecessary or

226 excessive realignment surgery or lateral release. This
 227 can be evaluated by Fulkerson's relocation test.¹⁵ This
 228 test is performed by holding the patella in a medial
 229 direction with the knee extended. The knee is then
 230 flexed while the patella is simultaneously released. This
 231 causes the patella to relocate into the trochlea. In
 232 patients with medial subluxation this test reproduces
 233 the patient's symptom. Patellar tracking can be assessed
 234 with the "J" sign. The patient extends the knee from 90°
 235 of flexion and the patella moves in a proximal and lat-
 236 eral direction that is similar to an inverted "J." This may
 237 be an observation in a patient presenting with PF mala-
 238 lignment or in otherwise normal knees. Likewise, a
 239 patella that is always lateral may have linear tracking
 240 even though there is malalignment.

241 Tightness of the quadriceps, hamstring, gastrocne-
 242 mius muscles, and iliotibial band may contribute to
 243 anterior knee pain and should be evaluated. Quadriceps
 244 tightness is suggested by: (1) a different degree of flex-
 245 ion of one knee (best documented prone) compared to
 246 the other, (2) feeling of tightness in the anterior aspect
 247 of the thigh, and (3) elevation of the pelvis due to flex-
 248 ion of the hip.⁴³ Evaluation of iliotibial band tightness
 249 is done using Ober's test. To perform this test the
 250 patient lies on the nonpainful side and the examiner
 251 flexes the affected knee and hip to 90°. The examiner
 252 then abducts and extends the affected thigh, which
 253 places the iliotibial band on maximal stretch. Palpation
 254 of the iliotibial band just proximal to the lateral femo-
 255 ral condyle during maximal stretch will cause severe
 256 pain in patients with excessive iliotibial band tightness.
 257 To test pelvic tilt, the Thomas test is performed with
 258 full hip flexion while observing pelvic movement.

259 42.4 Imaging

260 Plain radiographs are a standard part of the diagno-
 261 stic workup for cartilage-related patellofemoral
 262 pain. A standard series includes a standing AP view,
 263 45° (PA "Rosenberg, Shuss or skier view"), a true
 264 lateral view, and a low flexion angle axial view
 265 (Merchant). The AP view supplemented with a hip
 266 to ankle alignment film is used to evaluate the extent
 267 of varus or valgus alignment and joint space nar-
 268 rowing. The lateral view is useful for documenting
 269 trochlear dysplasia, patellar height (alta or infera),
 270 and patellar tilt. Currently, the methods of Caton-
 271 Deschamps or Blackburn-Peel are favored over

272 Insall-Salvati. The ratio compares the length of the
 273 articular surface of patella and the distance from the
 274 most anterior point of articular tibial surface to the
 275 most distal point of articular patella surface. Normal
 276 ratios are between 0.8 and 1.2. An index greater
 277 than 1.3 represents patella alta, and an index less
 278 than 0.6 represents patella infera. Dejour et al. have
 279 shown that the true lateral radiograph provides more
 280 information to assess trochlear dysplasia and patel-
 281 lar tilt than the Merchant view.^{2,4,11,17,26} The axial
 282 radiograph (Merchant view) is best used to deter-
 283 mine information regarding the sulcus angle, joint
 284 space narrowing, subchondral sclerosis, and shape
 285 of the patella.

286 CT scan is a useful imaging modality when a tibial
 287 tuberosity osteotomy is being considered. The TT-TG
 288 (tibial tubercle to trochlear groove) distance can be
 289 measured and can guide the surgeon in decision mak-
 290 ing about the need for an osteotomy. A TT-TG dis-
 291 tance of <15 mm is considered normal; values
 292 >20 mm are "excessive" and represent malalignment
 293 that may be treated with an osteotomy.^{4,40} Schutzer
 294 et al. identified three patterns of malalignment using
 295 CT imaging: type 1 (patellar subluxation without tilt),
 296 type 2 (patellar subluxation with tilt), and type 3
 297 (patellar tilt without subluxation).³⁵ For cartilage spe-
 298 cific considerations, a CT arthrogram will allow
 299 detailed assessment of lesion position and dimen-
 300 sions. As malposition of the patella relative to the tro-
 301 chlea is often associated with cartilage lesions,
 302 additional information may, at times, be obtained
 303 from multiple flexion angles (midwaist patellar slices
 304 or midwaist patellar cuts comparing quad-active and
 305 quad-relaxed views).³⁴

306 Magnetic resonance imaging (MRI) remains essen-
 307 tial for the evaluation of osteochondral lesions; in par-
 308 ticular the sagittal and coronal image series are useful
 309 in evaluating the patellofemoral articulation. MRI has
 310 received increased attention due to newly developed
 311 high-resolution imaging protocols with the option of
 312 enhancement by intravenous gadolinium. This results
 313 in sensitivity and specificity approaching 90% for MRI
 314 protocols using a 1.5 T magnet with appropriate
 315 orthogonal sequences.^{32,35,44} MRI also allows assess-
 316 ment of bone overload as evidenced with bone edema
 317 (bone bruise).

318 Bone scans are rarely used in standard cases, but
 319 can delineate sites of bone overload or in atypical pre-
 320 sentations can be an aid in diagnosing complex regional
 321 pain syndrome.

322 42.5 Basic Science

323 The lack of vascular, neural, and lymphatic access to
 324 articular cartilage creates an environment of limited
 325 repair. Injuries that penetrate the subchondral bone ini-
 326 tiate a vascular proliferative response resulting in a
 327 combination of normal hyaline cartilage (primarily
 328 type II collagen) and a structurally inferior fibrocarti-
 329 lage (primarily type I collagen). Each zone of normal
 330 hyaline cartilage has a characteristic composition of
 331 chondrocytes, collagen, aggrecan, and fluid dynamics
 332 that relate directly to that zone's function. Hyaline car-
 333 tilage consists of 4 zones with the most superficial zone
 334 containing the "lamina splendens" (packed collagen
 335 fibers) and a cellular layer of flattened chondrocytes.
 336 The preservation of this layer is very important for the
 337 deeper layers as it limits passage of large molecules
 338 between the synovial fluid and cartilage. The interme-
 339 diate zone is composed of spherical chondrocytes, pro-
 340 teoglycans, and obliquely oriented collagen fibers. The
 341 deep zone is a combination of collagen fibers and chon-
 342 drocytes oriented perpendicular to the articular surface
 343 which allows them to optimally resist compressive
 344 loads. The deepest level is the calcified cartilage layer
 345 which is separated from the deep zone by the tidemark.
 346 There are many classification systems used to describe
 347 chondral lesions. We have summarized the most com-
 348 monly used and present them in Table 42.1.

349 42.6 Patellofemoral Chondrosis Subsets

350 The cartilage in the patellofemoral articulation is the
 351 thickest articular cartilage in the body to accommodate
 352 the high loads that are seen in this joint. The variability
 353 of bony morphology of this articulation can be a chal-
 354 lenge for surgical treatment of the patellofemoral joint.
 355 It is useful to categorize patients with PF chondral dis-
 356 ease into two categories: those patients with PF chon-
 357 drosis and associated tibiofemoral chondrosis and those
 358 with isolated PF chondrosis. Patients with associated
 359 tibiofemoral chondrosis are common. As multiple com-
 360 partments are affected the outcomes in this patient
 361 group are less optimal than in the isolated condition. In
 362 order to maximize the outcomes in this patient group
 363 the concomitant lesions should be addressed at the same
 364 time as the primary procedure. Although, some consid-
 365 eration is given to treating only the most symptomatic
 366 lesions as occasionally lesions may be incidental and

not clinically relevant. Isolated patellofemoral chon- 367
 drosis can be divided by etiology into different catego- 368
 ries: traumatic, dysplastic, and focal osteochondral 369
 defects. The traumatic lesions are subdivided by mech- 370
 anism into those due to macrotrauma (such as a patellar 371
 dislocation or direct blow) and those due to microtrauma 372
 (which includes repetitive overuse injuries). Micro- 373
 traumatic lesions can present with linear fissures of the 374
 patella, traumatic delamination, or osteochondral frac- 375
 tures, depending on the degree of knee flexion at the 376
 time of the injury. Lesions due to dysplastic conditions 377
 result from increased contact pressure. Chondral pathol- 378
 ogy due to dysplasia can be difficult to treat because of 379
 the patellofemoral morphology. These lesions have 380
 been treated with soft tissue procedures and TTOs with 381
 variable results. Focal osteochondral defects not caused 382
 by trauma may be a result of avascular necrosis or 383
 osteochondritis dessicans. Lesions secondary to this 384
 type of pathology are rare in the patellofemoral joint. 385
 Treatment of these lesions requires the surgeon to cor- 386
 rect both the underlying bony pathology as well as the 387
 chondral defect. 388

42.7 Treatment and Indications/ Contraindications 389

42.7.1 Arthroscopic Chondral Debridement 392

Chondroplasty is indicated in low demand patients 393
 who have failed nonoperative treatment with therapy, 394
 NSAIDs, and injections or as a staging procedure in 395
 patients who may undergo a definitive cartilage restor- 396
 ative procedure. Though not a definitive time period, a 397
 trial of nonoperative management for 8–26 weeks is 398
 reasonable. This procedure is optimal for those patients 399
 with mechanical symptoms without widespread degener- 400
 ative changes. It may be the first line of treatment in 401
 younger patients with chondral defects and can be 402
 coupled with procedures such as biopsy for ACI for 403
 future interventions or planning a definitive major 404
 restoration. Goals of this procedure are to stabilize 405
 loose chondral flaps and decrease synovial inflamma- 406
 tion from recurrent sloughing of articular debris. 407
 Chondral debridement is of questionable value in the 408
 truly degenerative knee as several studies have failed 409
 to show efficacy over nonoperative treatment.³⁰ 410

411 **42.7.2 Microfracture (Marrow** 412 **Stimulation)**

413 Microfracture is indicated in younger patients with
414 full-thickness, well-contained, small lesions. It is ide-
415 ally suited for unipolar disease. Though some authors
416 have reported good outcomes with larger PF lesions,
417 other authors report poor results of marrow stimulation
418 for all patellar lesions.^{25,38} Most reports suggest treat-
419 ment for lesions under 4 cm^{27,24,29} Perhaps the most
420 important aspect of this surgery is the adherence to the
421 postoperative rehabilitation. This procedure is attrac-
422 tive because it is easy to perform and does not require
423 any additional implants.

424 Marrow stimulation is contraindicated when there
425 is uncorrected malalignment, global, diffuse degenera-
426 tive change, or an unwillingness or inability to comply
427 with postoperative rehabilitation demands. A relative
428 contraindication is age >40 years based on the Kreuz
429 outcomes.²⁵

430 **42.7.3 Osteochondral Autograft** 431 **Transplantation**

432 Osteochondral autograft transplantation is indicated
433 for a patellofemoral lesion of less than 2.5 cm² when
434 the lesion is contained. It is contraindicated in uncon-
435 tained lesions, bipolar lesions, or when there is uncor-
436 rected malalignment.

437 **42.7.4 Autologous Chondrocyte** 438 **Implantation/Transplantation**

439 ACI is indicated in symptomatic, full-thickness defects
440 of the patellofemoral articulation and in the United
441 States it is a second-line treatment. Larger lesions and
442 bipolar disease can be treated successfully with this
443 technique. This is a treatment option for larger lesions
444 and those lesions that have failed other techniques
445 (unless extensive bone loss is present) noting that it is
446 unclear which prior procedures may portend a less
447 optimal result.²⁸ Results appear to be better with uni-
448 polar disease, but focal bipolar disease can be success-
449 fully treated. The published series of ACI at the PF

compartment often includes significant number of 450
concomitant tibial tuberosity osteotomies; however 451
the technique and discussion of this technique are 452
addressed in a separate chapter in this text (Chap. 40). 453
Relative contraindications to ACI exist when there is 454
subchondral bone collapse or bone loss, uncorrectable 455
malalignment, untreated ligamentous instability, 456
advanced age (>55 years), widespread osteoarthritis, 457
and BMI >30. 458

459 **42.7.5 Osteochondral Allograft** 460 **Transplantation**

Osteochondral allograft transplantation is indicated for 461
patients with symptomatic, large (>3 cm²), full-thick- 462
ness osteochondral or full-thickness chondral lesions. 463
It is often used for second-line treatment of unstable 464
and irreparable osteochondritis desiccans lesions, 465
failed osteochondral autograft transfers, failed ACI, or 466
in the setting of subchondral bone collapse. The pathol- 467
ogy should be monopolar as bipolar lesion treatment 468
has a much lower success rate. Patients with advanced 469
or diffuse degenerative changes involving one or both 470
of the tibiofemoral compartments are contraindicated 471
for this procedure and are better served by knee 472
arthroplasty. 473

Authors preference: For pure chondral pathology, 474
ACI is performed concomitantly with straight anter- 475
ization if the TT–TG is normal or anteromedialization 476
when the TT–TG is excessive. Isolated bipolar dis- 477
ease of the PF joint in very young and severely symp- 478
tomatic patients who fail ACI may be treated with 479
fresh OC grafting of both the patella and trochlea 480
given the limited alternatives other than PF resurfac- 481
ing or total knee arthroplasty. Failed ACI of the PF 482
joint can be treated with revision osteochondral 483
allografting. 484

485 **42.8 Surgical Technique**

Prior to any major surgical restoration effort it is 486
important to have a recent and accurate intra-articular 487
evaluation of the patient's anatomy and chondral 488
defect. If recent, high-quality arthroscopic images 489
or video are unavailable, a diagnostic "staging" 490

491 arthroscopy should be performed at a date prior to the
492 restoration. When ACI is indicated, a biopsy would be
493 harvested at this surgery.

494 **42.8.1 Microfracture**

495 **42.8.1.1 Lesion Preparation**

496 Standard arthroscopic evaluation is carried out and the
497 lesion is identified. All other intra-articular pathology
498 should be addressed prior to performing the microfrac-
499 ture. The lesion is debrided with a curette and mechan-
500 ical shaver to expose the subchondral bone. It is
501 imperative to create a stable “well shouldered” lesion
502 in order to maximize the success of this procedure.
503 A ring curette can be helpful in the patellofemoral joint
504 for this purpose. When preparing a lesion on the under-
505 surface of the patella, it is often helpful to have an
506 assistant provide counter-pressure and stabilize the
507 patella to aid in the preparation of the lesion or per-
508 form a miniarthrotomy to allow unencumbered access.
509 It is also important to remove the calcified cartilage
510 layer in order to fully prepare the lesion.

[AU5]1 **42.8.1.2 Microfracture**

512 Once the lesion is prepared, a microfracture awl is
513 selected that will allow for perpendicular creation of
514 the holes. The goal is to place the holes 3–4 mm apart
515 and to a depth of 2–4 mm or just until fat globules are
516 seen coming from the underlying marrow (Fig. 42.1).
517 It is often helpful to begin the microfracture at the




Fig. 42.1 Marrow stimulation of trochlea

periphery of the lesion and work from outside in to
518 maximize the amount of holes that can be created. 519
Once the holes have been created the arthroscopy fluid 520
pressure is turned down or off to ensure that blood 521
flows from the created microfracture sites. The arthro- 522
scope is withdrawn and the wounds are closed in a 523
standard fashion. A recent basic science study suggests 524
the older form of marrow stimulation, drilling, may 525
have theoretical advantages.⁹ 526

42.8.2 Osteochondral Autograft 527

42.8.2.1 Exposure 528

The patient is positioned supine on an operating table. 529
The exposure for this procedure is similar to both ACI 530
and osteochondral allografting utilizing a midline util- 531
ity approach and either a medial or lateral arthrotomy. 532

42.8.2.2 Recipient Site Preparation 533

The lesion is sized with commercially available 534
instrumentation and an appropriately sized reamer is 535
selected. The diameter of the reamer should corre- 536
spond to the diameter of the grafts that are harvested 537
and each recipient hole should be separated by 1–2 mm. 538
Additionally, it is often helpful to allow for an addi- 539
tional 1–2 mm of depth to aid in graft implantation. 540
The holes can be further dilated to facilitate implanta- 541
tion if desired. 542

42.8.2.3 Graft Harvest 543

There are three major donor sites available for har- 544
vest of autogenous tissue: the lateral femoral condyle 545
above the sulcus terminalis, the superolateral 546
aspect of the intercondylar notch (if uninvolved), or 547
the peripheral aspect of the medial femoral condyle. 548
If the medial condylar donor site is to be used a 549
medial arthrotomy will assist in the harvest. Ideally 550
the largest size plug possible (1 cm²) is harvested. In 551
the case of larger lesions multiple plugs can be har- 552
vested. Most commercially available systems have a 553
T-handle device that is used to gather the donor tis- 554
sue. This device should be placed perpendicular to 555
the articular surface for the harvest. This device is 556

557 impacted to roughly 15 mm and the plug is then
558 rotated free from the surrounding tissue. The depth
559 of the graft is measured and used as a guide for cre-
560 ation of the recipient hole.

561 **42.8.2.4 Graft Implantation**

562 The graft remains in the delivery tube and is then
563 placed perpendicular to the recipient site and held in
564 place firmly. It is imperative to limit the number of
565 mallet strikes and the force of each strike when impact-
566 ing the graft with the plunger as excessive force may
567 lead to chondrocyte death. With the graft nearly com-
568 pletely in place, the tube is removed and gentle impac-
569 tion is used to seat the graft flush to the surrounding
570 articular cartilage. For larger defects it is beneficial to
571 prepare each graft and recipient site separately until
572 the defect is filled completely.

573 **42.8.3 Autologous Chondrocyte** 574 **Implantation (ACI)**

575 PF ACI is often performed in conjunction with a tibial
576 tuberosity osteotomy. The technique for AMZ is dis-
577 cussed in detail in other chapters and this section
578 focuses on ACI. In the United States currently matrix
579 autologous chondrocyte implantation (MACI) or other
580 scaffold techniques are not approved for clinical use
581 by the FDA. The current method utilized in the US
582 involves an open procedure with use of a periosteal
583 patch or off label usage of a collagen patch.^{8,16}

584 **42.8.3.1 Exposure**

585 A midline utility incision is utilized in all cases. If the
586 patient has a previous anterior knee incision, all
587 attempts are made to incorporate this in the skin inci-
588 sion. As previously discussed this procedure is often
589 performed in conjunction with a tibial tubercle osteot-
590 omy and if this is planned, the incision should extend
591 from the proximal pole of the patella to 8 cm distal to
592 the tibial tubercle. If an ACI is performed in isolation,
593 the incision can end at the level of the tibial tubercle.
594 Sharp dissection is carried out through the skin and
595 subcutaneous tissue and full-thickness flaps are

596 created. A lateral arthrotomy allows adequate exposure
597 and may have less morbidity as it spares the vastus
598 medialis. The arthrotomy extends from the level of the
599 vastus lateralis to the anterior capsule, being careful to
600 avoid injury to the anterior lateral meniscus. It is help-
601 ful to release the fat pad and to dissect the anterior horn
602 of the meniscus from the capsule as this can increase
603 the exposure of the trochlea. Variable amounts of knee
604 flexion are utilized to maximize the view of the tro-
605 chlea. The patella is subluxated and or everted medi-
606 ally to expose the trochlea.

607 **42.8.3.2 Recipient Site Preparation**

608 A fresh #15 blade is then used to create vertical walls at
609 the periphery of the chondral lesion. A ring curette is
610 then used to debride the chondral defect and remove all
611 abnormal cartilage, fibrocartilage with preservation of
612 the calcified cartilage layer. It is important to create a
613 “well shouldered” recipient site at this point of the pro-
614 cedure (Fig. 42.2a). Great care should be taken not to
615 gouge the underlying subchondral bone so as to avoid
616 bleeding. Once the lesion is prepared, a template is
617 pressed into the defect and is sized to cover the defect.
618 At this point the tourniquet is deflated and care is taken
619 to achieve homeostasis. Often, especially in the case of
620 revision for a failed microfracture, bleeding is encoun-
621 tered. It is imperative to obtain meticulous hemostasis
622 as bleeding in the recipient site may theoretically lead
623 to reduced production of hyaline-like cartilage. The use
624 of thrombin soaked gel-foam and small neuro paddies
625 can assist in this step. If the bleeding is difficult to con-
626 trol a small amount of fibrin glue can be applied to the
627 base of the recipient site and pressure can be applied for
628 3–5 min. It is important to ensure that there is adequate
629 surrounding cartilage available to pass suture through
630 in order to provide secure fixation of the patch.

631 **42.8.3.3 Patch Preparation and Fixation**

632 The patch is cut to match the template of the defect.
633 Classically, the patch is sutured by passing interrupted
634 6-0 Vicryl sutures from the patch through the sur-
635 rounding cartilage to achieve a water tight seal and the
636 ACI cell suspension is injected deep to the patch
637 (Fig. 42.2b). Suture passage can be facilitated by run-
638 ning the Vicryl through mineral oil prior to sewing.

[AU5]




Fig. 42.2 (a) The defect is cleared without penetrating the subchondral bone. Walls are vertical. (b) The periosteal patch or collagen patch is secured with suture and sealed with fibrin glue. The suspension of cultured chondrocytes is injected deep to the patch

639 The knots should be tied on the patch side, near the
 640 interface of the patch and surrounding cartilage.
 641 Occasionally if there is an area that is uncontained,
 642 suture anchors can be placed to provide additional
 643 fixation. Alternatively, the cells may be seeded on a
 644 collagen patch.³⁹ Ten minutes after seeding, the patch
 645 is sewn into place in the same manner as with the clas-
 646 sical use of periosteum. A small area may be left open
 647 to allow for injection of the additional chondrocyte
 648 suspension.

649 42.8.3.4 Sealing the Patch

650 Once sutured into place, fibrin glue is used to complete
 651 the seal. Care should be taken to use the minimal

amount of glue necessary to ensure an adequate seal. If
 cells are not seeded, the seal can then be tested with
 saline.

42.8.4 Osteochondral Allografting

42.8.4.1 Preparation of Recipient Site

There are several commercially available systems that
 can be used to size and prepare both the recipient site
 and the donor plug. Once the site has been sized a
 guidepin is placed and a cannulated reamer is used to
 create a socket with a depth of 6–8 mm. The sidewalls
 are then trimmed sharply with a fresh #15 blade and
 the site is irrigated and dried. Once this is complete
 the depth of the cylindrical socket is measured at the 12, 3,
 6, and 9 o'clock positions and this is recorded.
 Alternatively for a full-area lesion of the patella and/or
 trochlea, shells may be created free hand.

42.8.4.2 Preparation of the Donor Plug

The ideal donor site is then identified from the fresh
 osteochondral allograft donor tissue. Though diffi-
 cult, the goal is to match the native radius of curva-
 ture with that of the donor tissue. Once identified the
 donor is marked with a sizing tube. The donor tissue
 is fixed in a commercially available jig and a donor-
 harvesting device is used to core out the donor plug.
 The graft is then extracted and the measurements
 made previously of the recipient socket are applied to
 the donor plug to ensure accurate depth matching.

42.8.4.3 Graft Insertion/Fixation

The recipient site is then dilated an additional 0.5 mm
 with a commercially available dilation device. The
 graft is then press-fit into the recipient site with the
 least amount of force necessary because excessive
 force has been shown to lead to chondrocyte injury and
 death. Occasionally an oversized tamp may be required
 to complete the seating of the graft. For the freehand
 shell technique, the host bone is cut in the same man-
 ner as for a patellofemoral arthroplasty and the shells
 are shaped to have minimal bone (usually composite
 thickness of 5–8 mm) with the goal to establish a

691 normal composite thickness (Fig. 42.3a–c). Headless,
 692 variable pitch, bioabsorbable screws may be used to fix
 693 the shell allografts or to augment the fixation of
 694 allograft plugs.

695 42.9 Postoperative Management

696 Note that if concomitant tibial tuberosity surgery is
 697 performed, the weight-bearing recommendations of
 698 that procedure take precedence (see Chap. 40).

699 42.9.1 Microfracture-Trochlear/Patellar 700 Defect

701 All patients use continuous passive motion (CPM)
 702 from the day of the surgery for a period of 4–6 weeks,
 703 6–8 h per day. Patients with patellar and trochlear
 704 groove lesions should be placed immediately in a
 705 hinged brace with a 30°–45° flexion stop for at least
 706 8 weeks. Weight bearing in extension as tolerated is
 707 allowed immediately postoperatively. After the period
 708 of protected flexion, patients begin active range of
 709 motion exercises and progress to full flexion. No cut-
 710 ting, twisting, or jumping sports are allowed until at
 711 least 6 months after surgery.

712 42.9.2 Osteochondral Autograft 713 Transplantation

714 The postoperative management for this procedure is
 715 similar to that of both ACI and osteochondral
 716 allografting.

717 42.9.3 Autologous Chondrocyte 718 Implantation of the 719 Patellofemoral Joint

720 The operative extremity is placed into a hinged knee
 721 brace locked in full extension postoperatively.
 722 Continuous passive motion is initiated on the first post-
 723 operative day (0–30°; 1 cycle/min) in 2-h increments
 724 for 6–8 h per day. Range of motion is advanced by 15°
 725 each week with the use of the continuous passive




Fig. 42.3 The area of chondrosis is identified (a). The bony cuts are made with a cooled oscillating saw (b). The donor graft is shaped to fit the defect and secured (c)

726 motion machine and simultaneous unlocking of the 726
 727 brace. The objective is to obtain 90° of flexion by 727
 728 weeks 6–8, but not generally sooner than 4 weeks. 728

729 Return to full activity is not permitted until 8 months
 730 postoperatively to protect the lesion until the cartilage
 731 has sufficiently matured.

defects (2–3 cm²). However larger lesions and high- 750
 demand patients were better treated with autologous 751
 chondrocyte implantation or osteochondral grafting. 752

732 **42.9.4 Osteochondral Allograft and**
 733 **Autograft Transplantation**

734 Postoperatively, if the procedure is performed appro-
 735 priately with a well-contained defect, early weight
 736 bearing and motion are encouraged. After a multiple-
 737 plug technique, full range of motion and protected
 738 weight bearing are advised for the first 4 weeks. At
 739 4 weeks, full weight bearing is allowed. Sporting
 740 activities are not recommended until 4–6 months
 741 postoperatively.

42.10.2 Autologous Chondrocyte
Implantation

Recent results of autologous chondrocyte implantation 755
 in the patellofemoral joint have been encouraging with 756
 good and excellent results even in patients with large 757
 defects (average 10 cm²) who had previously under- 758
 gone an average of three surgeries. It appears that con- 759
 comitant realignment procedures are an important 760
 adjunct in obtaining these favorable results. 761

742 **42.10 Outcomes**

743 A detailed description of the studies evaluating out-
 744 comes from the various procedures is included in
 745 Table 42.2. Below is a summary of these findings.

42.10.3 Osteochondral Grafting:
Autograft Transplantation

Transfer of autologous osteochondral plugs is limited 764
 by the donor area and donor site morbidity. Based on 765
 such limitations, this technique is employed for only 766
 small-sized defects. Published studies have reported 767
 varying outcomes, suggesting that this technique be 768
 suitable for the relatively rare patient who presents 769
 with a small isolated chondral defect. 770

746 **42.10.1 Microfracture**

747 Marrow stimulation techniques result in a repair tissue
 748 with inferior wear characteristics. Some authors have
 749 reported good results in the treatment of smaller

t2.1 **Table 42.2** Summary of various authors’ outcomes of specified patellofemoral surgical techniques

t2.2	Procedure	Authors	Reported outcomes
t2.3	Microfracture	Blevins et al. ⁵	Good results with microfracture in lesions 2–3 cm ²
t2.4		Kreuz et al. ²⁵	
t2.5		Steadman et al. ³⁸	
t2.6		Miller et al. ²⁷	
t2.7		Mithoefer et al. ²⁹	
t2.8	Steadman et al. ³⁸	Lysholm score 53.8–83, Tegner score 2.9 → 4.5	
t2.9	Kreuz et al. ²⁵		
t2.10	ACI(PF)	Minas et al. ²⁸	Good and excellent results in up to 85%
t2.11		Bentley et al. ³	
t2.12		Bitteberg et al. ⁶	
t2.13		Yates ⁴⁵	
t2.14	OA grafting	Hangody et al. ¹⁸	Good results 80% of patients Others have shown failure rates that approached 100% when used for patellar defects 86% good/excellent
t2.15		Bentley et al. ³	
t2.17		Jakob et al. ²¹	
t2.18	Allograft transplantation	Jamali et al. ²²	Graft survival in 60–70% of patients with follow-up of up to 10 years
t2.19		Torga et al. ⁴¹	
t2.20		Shasha et al. ³⁶	
			Kaplan–Meier Survival Rate: 5 years – 95%, 10 years – 80%, 15 years – 65%, 20 years – 46%

771 **42.10.4 Osteochondral Grafting:** 772 **Allograft Transplantation**

773 This type of reconstruction appears to be better suited
774 for the treatment of trochlear defects, though some
775 authors have reported good outcomes with allograft
776 reconstruction of the patella and even bipolar lesions.

777 **42.11 Conclusion**

778 Management of patients with a PF joint that presents
779 with pain and dysfunction associated with chondral
780 pathology remains a difficult clinical problem. Attention
781 to the entire PF system including issues pertaining
782 to alignment is paramount in achieving a successful
783 outcome. Similar to the tibiofemoral joint, all comor-
784 bidities must be addressed. Multiple options exist to
785 manage the chondral pathology and are chosen based
786 upon defect size and location. Outcomes support good
787 and excellent results similar to that seen with the man-
788 agement of the tibiofemoral joint.

789 **References**

- 790 1. Aroen A, Loken S, Heir S, et al. Articular cartilage lesions in
791 993 consecutive knee arthroscopies. *Am J Sports Med.*
792 2004;32:211-215.
- 793 2. Beaconsfield T, Pintore E, Maffulli N, et al. Radiological
794 measurements in patellofemoral disorders. A review. *Clin*
795 *Orthop Relat Res.* 1994;308:18-28.
- 796 3. Bentley G, Biant LC, Carrington RW, et al. A prospective,
797 randomised comparison of autologous chondrocyte implanta-
798 tion verses mosaicplasty for osteochondral defects in the
799 knee. *J Bone Joint Surg Br.* 2003;85:223-230.
- 800 4. Biedert RM. *Patellofemoral Disorders. Diagnosis and*
801 *Treatment.* West Sussex: Wiley; 2004.
- 802 5. Blevins FT, Steadman JR, Rodrigo JJ, et al. Treatment of
803 articular cartilage defects in athletes: an analysis of func-
804 tional outcome and lesion appearance. *Orthopedics.*
805 1998;21:761-767.
- 806 6. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep
807 cartilage defects in the knee with autologous chondrocyte
808 transplantation. *N Engl J Med.* 1994;331:889-895.
- 809 7. Brittberg M, Peterson L, Sjiogren-Jansson E, et al. Articular
810 cartilage engineering with autologous chondrocyte trans-
811 plantation. *J Bone Joint Surg Am.* 2003;85:109-115.
- 812 8. Brittberg M, Tallheden T, Sjiogren-Sansson B, et al.
813 Autologous chondrocyte used for articular cartilage repair:
814 an update. *Clin Orthop Relat Res.* 2001;391:337-348.
9. Chen H, Sun J, Hoemann CD, et al. Subchondral structure 815
and repair responses following bone marrow stimulation by 816
drilling versus microfracture in rabbit trochleas. ICERS; 2009; 817
Miami. 818
10. Curl WW, Krome J, Gordon ES, et al. Cartilage injuries: a 819
review of 31,516 knee arthroscopies. *Arthroscopy.* 820
1997;13:456-460. 821
11. Dejour H, Walch G, Nove-Josserand L, et al. Factors of 822
patellar instability: an anatomic radiographic study. *Knee*
Surg Sports Traumatol Arthrosc. 1994;2:19-26. 823
824
12. Ficat P, Ficat C, Bailleux A. External hypertension syndrome 825
of the patella. Its significance recognition arthrosis. *Rev Chir*
Orthop Reparatrice Appar Mot. 1975;61:39-59. 826
827
13. Ficat P, Hungerford D. *Disorder of the Patellofemoral Joint.* 828
Baltimore: Williams & Wilkins; 1977. 829
14. Fulkerson JP. The etiology of patellofemoral pain in young, 830
active patients: a prospective study. *Clin Orthop Relat Res.* 831
1983;179:129-133. 832
15. Fulkerson JP. A clinical test for medial patella tracking. *Tech*
Orthop. 1997;12:165-169. 833
834
16. Gomoll AH, Probst C, Farr J, et al. Use of type I/III bilayer 835
collagen membrane decreases reoperation rates for symp- 836
tomatic hypertrophy after autologous chondrocyte implanta- 837
tion. *Am J Sports Med.* 2009;35:20S-23S. 838
17. Grelsamer RP, McConnell J. *The Patella. A Team Approach.* 839
Gaithersburg: Aspen Publication; 1998. 840
18. Hangody L, Rathonyi GK, Duska Z, et al. Autologous osteo- 841
chondral mosaicplasty. Surgical technique. *J Bone Joint*
Surg Am. 2004;86:65-72. 842
843
19. Hejgaard N, Arnoldi CC. Osteotomy of the patella in the 844
patellofemoral pain syndrome. The significance increased 845
intraosseous pressure during sustained knee flexion. *Int*
Orthop. 1987;8:89-94. 846
847
20. Hjelle K, Solheim E, Strand T, et al. Articular cartilage 848
defects in 1,000 knee arthroscopies. *Arthroscopy.* 849
2002;18:730-734. 850
21. Jakob RP, Franz T, Gautier E, et al. Autologous osteochon- 851
dral grafting in the knee: indication, results and reflections. 852
Clin Orthop Relat Res. 2002;401:170-184. 853
22. Jamali AA, Emmerson BC, Chung C, et al. Fresh osteochon- 854
dral allografts. *Clin Orthop Relat Res.* 2005;437:176-185. 855
23. Kaplan LD, Schurhoff MR, Selesnick H, et al. Magnetic 856
resonance imaging of the knee in asymptomatic professional 857
basketball players. *Arthroscopy.* 2005;21:557-561. 858
24. Knutsen G, Engerbretsen L, Ludvigsen TC, et al. Autologous 859
chondrocyte implantation compared with microfracture in 860
the knee. A randomized trial. *J Bone Joint Surg Am.* 2004; 861
86:455-464. 862
25. Kreuz PC, Steinwachs MR, Erggelet C, et al. Results after 863
microfracture of full-thickness chondral defects in different 864
compartments in the knee. *Osteoarthritis Cartilage.* 865
2006;14(11):1119-1125. 866
26. Merchant AC. Radiography of the patellofemoral joint. *Oper*
Tech Sports Med. 1999;7:59-64. 867
868
27. Miller BS, Steadman JR, Briggs KK, et al. Patient satisfac- 869
tion and outcome after microfracture of the degenerative 870
knee. *J Knee Surg.* 2004;17:13-17. 871
28. Minas T, Bryant T. The role of autologous chondrocyte 872
implantation in the patellofemoral joint. *Clin Orthop Relat*
Res. 2005;436:30-39. 873
874

- 875 29. Mithoefer K, Williams RJ III, Warren RF, et al. The microfracture technique for the treatment of articular cartilage
876 lesions in the knee. A prospective cohort study. *J Bone Joint Surg Am.* 2005;87:1911-1920.
877
878
- 879 30. Moseley B, O'Malley K, Petersen N, et al. A controlled trial
880 of arthroscopic surgery for osteoarthritis of the knee. *N Engl J Med.* 2002;347:81-88.
881
- 882 31. Post WR. History and physical examination. In: Fulkerson
883 JP, ed. *Disorders of the Patellofemoral Joint.* 4th ed.
884 Philadelphia: Lippincott Williams & Wilkins; 2004.
- 885 32. Potter HG, Foo LF. Magnetic resonance imaging of articular
886 cartilage: trauma, degeneration, and repair. *Am J Sports Med.* 2006;34:661-667.
887
- [A] 888 33. Recht MP, Goodwin DW, Winalsky CS, White LM. MRI of
889 articular cartilage: revisiting current status and future directions. A journal review. *Am J Roentgenol.* 2005;185:899-914.
890
- 891 34. Schepesis AA, Fitzgerald M, Nicoletta R. Revision surgery for
892 exertional compartment syndrome of the lower leg: technique,
893 findings and results. *Am J Sports Med.* 2005;33:1040-1047.
- 894 35. Schutzer SF, Ramsby GR, Fulkerson JP. Computed tomographic classification of patellofemoral pain patients. *Orthop Clin North Am.* 1986;17:235-248.
895
896
- 897 36. Shasha N, Krywulak S, Backstein D, et al. Long-term follow-up of fresh tibial osteochondral allografts for failed tibial plateau fracture. *J Bone Joint Surg Am.* 2003;85:33-39.
898
899
- 900 37. Spencer JD, Hayes KC, Alexander IJ. Knee joint effusion and quadriceps inhibition in man. *Arch Phys Med Rehabil.* 1984;65:171-177.
901
902
38. Steadman JR, Briggs KK, Rodrigo JJ, et al. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. *Arthroscopy.* 2003;19:477-484.
903
904
905
906
39. Steinwachs M. New technique for cell-seeded collagen-matrix-supported autologous chondrocyte transplantation. *Arthroscopy.* 2009;25:208-211.
907
908
909
40. Teitge RA. Plain patellofemoral radiographs. *Oper Tech Sports Med.* 2001;9:134-151.
910
911
41. Torga Spak R, Teitge RA. Fresh osteochondral allografts for patellofemoral arthritis: long-term followup. *Clin Orthop Relat Res.* 2006;444:193-200.
912
913
914
42. Walczak BE, McCulloch PC, Kang RW, et al. Abnormal finding on magnetic resonance imaging in asymptomatic NBA players. *J Knee Surg.* 2008;21:27-33.
915
916
917
43. Walsh WM. Patellofemoral joint. In: DeLee JC, Drez D, eds. *Orthopaedic Sports Medicine. Principles and Practice.* Philadelphia: W.B. Saunders Company; 1994.
918
919
920
44. Winalski CS, Gupta KB. Magnetic resonance imaging of focal articular cartilage lesions. *Top Magn Reson Imaging.* 2003;14:131-144.
921
922
923
45. Yates JW. The effectiveness of autologous chondrocyte implantation for treatment of full-thickness articular cartilage lesions in workers' compensation patients. *Orthopedics.* 2003;26:295-301.
924
925
926
927

Author Queries

Chapter No.: 42

Query	Details Required	Author's Response
AU1	Please confirm corresponding author and also confirm author affiliation.	
AU2	In the sentence starting "For example, the chondrosis..." for completeness.	
AU3	Please confirm the heading "Microfracture."	
AU4	Please provide citation for Ref. [33].	
AU5	Please provide better quality figure.	